Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

2/1/24 4:05:00 PM ET

Medical Specialities

Health Care

Get the next $GH alert in real time by email

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, February 22, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240201204485/en/

Get the next $GH alert in real time by email

Recent Analyst Ratings for

$GH

Date	Price Target	Rating	Analyst
6/28/2024	$36.00	Neutral → Buy	Guggenheim
6/3/2024	$32.00	Buy	Jefferies
4/24/2024	$28.00	Buy	Craig Hallum
12/14/2023		Neutral	Guggenheim
12/13/2023		Peer Perform	Wolfe Research
11/13/2023	$27.00	Mkt Perform → Outperform	Raymond James
9/28/2023	$34.00	Outperform	Bernstein
9/27/2023	$40.00	Neutral → Overweight	Piper Sandler

More analyst ratings

Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

Chat with this insight

Recent Analyst Ratings for $GH

$GH Leadership Updates

Live Leadership Updates

Roberto A. Mignone Joins Guardant Health Board of Directors

Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors

Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer

$GH Press Releases

Fastest customizable press release news feed in the world

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

Guardant Health to Participate in Upcoming Investor Conferences

$GH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Guardant Health upgraded by Guggenheim with a new price target

Jefferies resumed coverage on Guardant Health with a new price target

Craig Hallum resumed coverage on Guardant Health with a new price target

$GH Market Insights

Live Market Insights

Guardant Health Launches Enhanced Guardant360 Test On Guardant Infinity Platform; New Test Covers 10 Times More Genes And Quantifies Tumor Burden With 10 Times Higher Sensitivity; Medicare And Major Private Payers Cover Test For Comprehensive Genomic Profiling Of Advanced Solid Tumors

Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast

B of A Securities Maintains Buy on Guardant Health, Raises Price Target to $40

$GH Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$GH Large Ownership Changes

This live feed shows all institutional transactions in real time.

$GH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Kalia Kumud bought $38,963 worth of shares (2,187 units at $17.82), increasing direct ownership by 21% to 12,722 units (SEC Form 4)

SEC Form SC 13G filed by Guardant Health Inc.

SEC Form SC 13G filed by Guardant Health Inc.

Amendment: SEC Form SC 13G/A filed by Guardant Health Inc.

Chief Information Officer Kalia Kumud sold $204,722 worth of shares (7,000 units at $29.25), decreasing direct ownership by 28% to 17,744 units (SEC Form 4)

Director Tariq Musa converted options into 250 shares, increasing direct ownership by 5% to 4,996 units (SEC Form 4)

Director Potter Myrtle S converted options into 68 shares, increasing direct ownership by 0.50% to 13,653 units (SEC Form 4)

$GH SEC Filings

SEC Form 144 filed by Guardant Health Inc.

SEC Form 10-Q filed by Guardant Health Inc.

Guardant Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$GH Financials

Live finance-specific insights

$GH FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024

Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

July 30, 2024 - FDA Roundup: July 30, 2024

May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

Recent Analyst Ratings for
$GH

$GH
Leadership Updates

$GH
Press Releases

$GH
Analyst Ratings

$GH
Market Insights

$GH
Insider Purchases

$GH
Large Ownership Changes

$GH
Insider Trading

$GH
SEC Filings

$GH
Financials

$GH
FDA approvals